Vertex Pharmaceuticals stock draws attention after kidney data

Published on 09/28/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals stock traded at USD 526.19 on September 28, 2026, after new inaxaplin data cut kidney biomarkers. JPMorgan raised its target to USD 560.00.

Bauhaus-Poster mit geometrischen Formen, Molekülsymbol und großem Schriftzug PHARMA — Vertex Pharma US92532F1003 zeigt ein geometrisches Bauhaus-Poster mit Sektor-Text PHARMA und stilisierter Molekülgrafik, Illustration mit AI erstellt.

Vertex Pharmaceuticals stock (ISIN US92532F1003) was last at USD 526.19 on Nasdaq on September 28, 2026, up USD 3.81, or 0.73 percent, from the prior close of USD 522.38. The market capitalization stood at USD 132.4 billion, while the day's range was USD 518.92 to USD 527.64.

Kidney data expand the pipeline

The latest company catalyst is inaxaplin, Vertex's investigational treatment for APOL1-mediated kidney disease. In a September 22, 2026 release, Vertex Pharmaceuticals reported a 42.70 percent reduction in urine albumin to creatinine ratio at Week 13 in the cohort with modest proteinuria.

The result was more limited in the cohort that also had type 2 diabetes. UACR declined 17.30 percent at Week 13, while the study enrolled 41 people across both groups. Vertex also completed enrollment in the Phase 2/3 AMPLITUDE trial and expects interim data in early 2027.

Revenue beats while EPS misses

Vertex's established business provides a second reference point. For the second quarter of 2026, revenue reached USD 3.33 billion, an increase of 12.50 percent from the prior-year quarter, according to MarketBeat. Adjusted EPS was USD 4.73 against a USD 4.74 consensus estimate, so revenue exceeded expectations while earnings per share missed by USD 0.01.

The contrast matters for investors because the kidney program is still clinical-stage, while cystic fibrosis products generate the operating base. JPMorgan reaffirmed an Overweight rating on September 11, 2026, and raised its price target from USD 515.00 to USD 560.00, according to MarketBeat.

Nasdaq valuation stays elevated

At USD 526.19, the stock was 6.42 percent below that JPMorgan target on September 28, 2026. The share price was also 5.75 percent below the 52-week high of USD 560.25, while the 52-week low was USD 384.39, according to the Nasdaq-listed market snapshot compiled by TradingView.

That leaves the valuation tied to two different timelines: commercial execution in 2026 and clinical validation in 2027. The next test for the thesis is whether inaxaplin can reproduce the AMPLIFIED signal in the larger AMPLITUDE program.